FindTrial
Sign In

Treatment with Tapentadol in Cancer Patients

Pharmacogenomics and Population Pharmacokinetic Integration for Precision Therapy of Tapentadol in Palliative Cancer Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/11/029206
Enrollment
110
Registered
2020-11-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G893- Neoplasm related pain (acute) (chronic)

Interventions

None listed

Sponsors

Manipal Academy of Higher Education
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of age >18 years and Patients with moderate to severe pain {pain >4 measured on numerical rating scale (NRS)}. Willing to participate in the study and provide written informed consent.

Exclusion criteria

Exclusion criteria: Pregnant/lactating women. Patients already on MAO inhibitors, serotonin reuptake inhibitors, and Tricyclic antidepressants [contraindicated drugs].

Design outcomes

Primary

MeasureTime frame
A treatment algorithm for Tapentadol therapy for pain management in palliative cancer patientsTimepoint: 3 years—

Secondary

MeasureTime frame
Pharmacogenomic profile and Population Pharmacokinetic model of TapentadolTimepoint: 3 years—

Countries

India

Contacts

Public ContactDr M Surulivel Rajan

Kasturba Medical College

naveen.salins@manipal.edu9969683669

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026